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Abstract A probiotic is a living micro-organism admin-
istered to promote the health of the host by treating or
preventing infections owing to strains of pathogens. Sac-
charomyces boulardii is a nonpathogen yeast that has a
direct inhibitory effect on the growth of many pathogens,
an anti-secretory effect and a trophic effect on enterocytes.
The aim of this study was to determine the effect of S.
boulardii on diarrhea in children. The children from
6 months to 6 years of age with acute watery diarrhea
admitted in pediatric clinic in Kashan in 2012 were
included in this trial. Exclusion criteria were high fever
(T[ 38.5 C), severe dehydration, bloody diarrhea, severe
malnutrition, using of antibiotics, anti-diarrheal or anti-
fungal drugs and children with more than one complain.
Two hundred patients were assigned into two groups: A
total of 100 patients were treated with S. boulardii in
addition to ORS (case group) and 100 patients were given
placebo in addition to ORS (control group). The duration of
diarrhea and frequency of stools were recorded by asking
the mothers of the children every day. The results showed
that the defecation frequency after second day of treatment
in the case group was significantly less than the control
group (P = 0.001) and the mean numbers of days of
diarrhea was significantly lower in the case group
(P = 0.001). The result of this study confirms that S.
boulardii reduces the frequency of stool and duration of
illness in children.
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Introduction
Diarrhea is a common manifestation of many gastroin-
testinal diseases. It means as a decrease in fecal consis-
tency and occurs when there is an imbalance between water
and ions intestinal absorption and secretion. Diarrheal
diseases are the most common health problems in the
developing countries and the first cause of hospitalization
in children [1]. Treatment of diarrhea basically consists
replacing of lost fluids by means of oral rehydration solu-
tion (ORS) [1–3]. The use of ORS in diarrhea reduces the
rate of mortality and morbidity of the disease but does not
lead to the decrease in the duration of diarrhea and its
intensity [4–7]. Testing different strategies to help in this
direction, probiotics appear as one of the alternatives cur-
rently under discussion that may shorten the duration of
diarrhea [4, 8]. The use of yoghurt (as a probiotic) in the
treatment of diarrhea has been known for a long time ago
[9].The United Nations and World Health Organization
define probiotics as ‘‘Live micro-organisms which when
administered in adequate amounts confer a health benefit
on the host’’ [9, 10]. Probiotics promote the health of the
host by treating or preventing infections owing to strains of
pathogens [9]. A few agents, including Lactobacillus GG,
Lactobacillus reuteri and Saccharomyces boulardii, seem
to be promising agents for the amelioration of the course of
acute diarrhea in children [9, 11]. Among these, all are
bacteria except S. boulardii which is yeast [9].
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Saccharomyces boulardii is a nonpathogenic, nontoxic
yeast strain. It is the tropical yeast found in a permanent
unicellular state, a eukaryote of the order endomycetales
[12]. It was first described in 1920 by the microbiologist
Henri Boulerd, who isolated the yeast from the skins of
lychee nuts from his travels in Indonesia [10, 13]. After he
had observed, it was eaten as an anti-diarrheal agent by the
local population [9, 12]. The yeast, which now bears his
name, is a substrain of Saccharomyces cerevisiae, has an
optimal growth in temperature of 37 C and survives pas-
sage through all levels of the GI tract [10]. It was subse-
quently used in France for the treatment of diarrhea in the
beginning of 1950 [9, 12]. Saccharomyces boulardii has a
direct antagonistic effect on many pathogens. Its efficacy is
attributed to a direct inhibitory effect on the growth of
pathogenic strains, an anti-secretory effect by specifically
binding toxins to intestinal receptors and a trophic effect on
enterocytes with stimulation of enzymatic activity and
nonspecific and anti-infectious mechanisms such as anti-
inflammatory activity [14]. Saccharomyces boulardii
secretes a protease which has been shown to neutralize
certain bacterial toxins. It is also able to stimulate an
immune response in the intestinal mucosa. It has a trophic
effect by enhancing the metabolic function of the mucosa
[9, 15]. Saccharomyces boulardii releases polyamines
which result in an increased secretion of brush border
disaccharidases and enzymes (such as lactase, sucrase,
maltase and aminopeptidase) [14]. The increased secretion
of polyamines enhances maturation of enterocytes.
Polyamines increase the glucose carrier activity on the
membrane of enterocytes which is essential to achieve
maximal glucose absorption [14]. This study was per-
formed in Kashan, Iran, to determine the effect of S.
boulardii on the clinical course of acute watery diarrhea in
children.
Subjects and methods
The children aged 6 months to 6 years with acute watery
diarrhea admitted in pediatric clinic in Kashan (Iran) in
2012 were included in this randomized controlled clinical
trial. Exclusive criteria were high fever (T[ 38.5 C),
severe dehydration, bloody diarrhea, severe malnutrition,
using of antibiotics, anti-diarrheal or antifungal drugs and
patients with more than one complain. Parents received
detailed information about the study, and those who agreed
to participate signed an informed consent. Patients were
alternately assigned to receive the probiotic (S. boulardii)
plus ORS or placebo plus ORS. Two hundred patients were
included in this trial and divided into two groups: A total of
100 patients were treated with S. boulardii that were pre-
pared by Ardegpharm-GmbH, 250 mg once daily in
addition to ORS (case group), and 100 patients were given
placebo in addition to ORS (control group). Placebo and
probiotic products have similar color and taste. They were
treated for 5 days. The ORS was administered by WHO
protocol for management of diarrhea. In the first visit on
admission data about full clinical history, physical exami-
nation, nutritional status, dehydration, fever, oral tolerance
and stool characteristics were recorded. The duration of
diarrhea, consistency and frequency of stool were recorded
by asking the mothers of the children every day during
active treatment phase (5 days). Diarrhea was defined as
the passing of three or more loose or watery stool for a day.
Diarrhea was considered to have stopped when the child
passed less than three stools per day or stool with solid
consistency. Data analysis was performed by using the
SPSS 16, and parametric statistical tests (t test and Chi-
square) were employed to compare the two groups.
Results
Kolmogrove–Smirnov test showed that data had normally
distributed; therefore, parametric statistical tests were
employed to compare the two groups.
Table 1 presents the demographic characteristics of the
children according to the treatment strategy and shows that
the proportion of the two groups with regard to gender was
not significantly different (P = 0.56).
Table 2 presents the mean value of age for both treat-
ment strategies and shows that there is no significantly
difference between the two groups (P = 0.17).
Table 3 presents duration of diarrhea according to the
treatment strategy and shows that is significantly less for
the case group than for the control group (3.4 vs 5.5 days)
(P = 0.001).
Table 4 presents the stool frequency of two groups
during the treatment. On day 1 of treatment, the defecation
frequency in two groups was similar (8.4 in the case and
8.1 in the control group) (P = 0.47). On day 2, it was 6.5 in
the case group and 7.2 in the control group that there was
no significant difference between two groups (P = 0.07).
On day 3, stool frequency was 3.2 in the case group and 5.3
Table 1 Demographic characteristics of the patients according to the
treatment strategy
Groups Frequency Gender
Girl Boy
Case 100 40 60
Control 100 44 56
Total 200 84 116
P value = 0.56
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in the control group, and there was a significant difference
between two groups (P = 0.001). On day 4, it was 2.1 for
the case group and 4.1 for the control group; that two
groups were different significantly (P = 0.001). On day 5,
stool frequency was significantly less for the case group
than for the control group (1.5 vs 3.2) (P = 0.001).
This table shows that the stool frequency was a signif-
icant reduction in the case group as compared to the control
group from the third day of treatment.
Discussion
This study aimed to investigate the effect of a yeast pro-
biotic (S. boulardii) in the treatment of acute gastroen-
teritis, and the results showed that the use of S. boulardii
can reduce the duration of diarrhea (3.4 days in the case
group versus 5.5 days in the control group). In one study
that conducted by Grandy in children 1–23 months of age,
hospitalized for acute diarrhea in Bolivia was seen that
total duration of diarrhea was significantly shorter in chil-
dren receiving S boulardii, and results show that S. bou-
lardii diminished the time of diarrhea by 31.4 % and
shortened time with fever by 73 %. The results of our study
about the duration of diarrhea are consistent with these
results [1]. In other study, Canani evaluate the efficacy of
probiotics in 571 children aged 3–36 months with acute
diarrhea in Italy [4]. Median duration of diarrhea was
significantly shorter in children who received probiotics
(78.5 h) than who received oral rehydration solution alone
(115.0 h). The results of our study are consistent with these
results [4]. In another study that performed by Htwe in 100
hospitalized children 3 months to 10 years in Belgium, 50
were treated with S. boulardii in addition to oral rehydra-
tion solution (ORS) and 50 were given ORS alone (control
group). The mean duration of diarrhea was 3.08 days in the
S. boulardii group and 4.68 days in the control group [14].
The results of our study are consistent with these results; of
course in our study, the probiotic was administered once
daily but in above study twice daily. In another study by
Billoo in Karachi, Pakistan, 100 children from 2 months to
12 years of age with acute diarrhea were randomized in S.
boulardii group (treated with ORS, nutritional support and
S. boulardii, 250 mg bid) and in control group (treated with
ORS and nutritional support only). The duration of diarrhea
was 3.6 day in S. boulardii group, whereas it was 4.8 day
in control group. Therefore, this study confirms that the S.
boulardii significantly reduces the frequency and duration
of acute diarrhea [9]. Our results are consistent with the
results of the above study. In the present study, defecation
frequency in the first and second days of treatment does not
show a significant difference between two groups
(P = 0.47). Defecation frequency in the third, fourth and
fifth day of treatment shows a significant difference
between two groups. The results of this study indicate that
the use of S. boulardii in the treatment of diarrhea can
significantly reduce the stool frequency from the third day
onwards.
In the Canani study was seen one day after the first
probiotic administration, the daily number of stools was
significantly lower in children who received probiotics [4].
The results of our study are consistent with these results. In
this study, efficacy of S. boulardii perceived after the first
day, but in our study was seen on the third day. In the
Table 2 Comparing the mean of age in treatment strategy
Groups Frequency Age (month) SD
Case 100 16.2 13.18
Control 100 18.2 14.76
Total 200 17.2 14.04
P value = 0.17
Table 3 Duration of diarrhea in both groups
Groups Frequency Mean (days) SD
Case 100 3.4 1.3
Control 100 5.5 2.1
P value = 0.001
Table 4 Stool frequency
during the treatment in both
groups
Day of treatment Groups Significance (P value)
Case Control
Frequency Mean SD Frequency Mean SD
Day 1 100 8.4 2.7 100 8.1 3.2 0.47
Day 2 100 6.5 1.8 100 7.2 3.5 0.07
Day 3 100 3.2 1.3 100 5.3 1.62 0.001
Day 4 100 2.1 0.65 100 4.1 1.45 0.001
Day 5 100 1.5 0.73 100 3.2 1.04 0.001
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Billoo study, stool frequency by day 3 was 2.7 in S. bou-
lardii group and 4.2 in control group, and by day 6 it was
1.6 in S. boulardii group versus 3.3 in control group. These
results showed that the S. boulardii significantly reduces
the frequency of acute diarrhea [9] that was similar to our
study. In another study that performed by Guillot in
Havana, Cuba, 40 babies aged 6–36 months with chronic
diarrhea were studied. The study confirms the beneficial
effect of S. boulardii in chronic diarrhea caused by a post-
gastroenteritis syndrome, especially when it is due to gia-
rdiasis. Reduction in stools frequency was significantly
lower in children who received probiotics [12].
In the study by Htwe was seen stools had a normal
consistency on day 3 in 76 % of patients in the S. boulardii
group compared with only 24 % in the control group. On
day 2, 54 % had less than three stools in the S. boulardii
group compared with only 30 % in the control group.
Saccharomyces boulardii shortens the duration of diarrhea
and normalizes stool consistency and frequency [14]. The
results of our study are consistent with these results.
Conclusion
The results of our study and other similar studies about
administration of the yeast probiotic proved that S. bou-
lardii can substantially reduce the severity and duration of
diarrhea in children. According to the efficacy of the bac-
terial probiotics on diarrhea recommended further studies
to be performed to compare the effects of bacterial and
yeast probiotics in children with gastroenteritis.
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